6672-69-1

Usage

InChI:InChI=1/C14H13N/c1-3-7-13-11(5-1)9-15-10-12-6-2-4-8-14(12)13/h1-8,15H,9-10H2

Upstream product

• 3864-08-2 diphenimide 
• 58335-98-1 6-benzyl-6,7-dihydro-5H-dibenz[c,e]azepine 
• 42773-01-3 2,2'-(2-azapropane-1,3-diyl)-1,1'-biphenyl-N-hydroxide 
• 31638-37-6 6,7-dihydro-5H-dibenzicazepine-7-one 
• 6747-35-9 2-carboxy-2'-(aminocarboxyl)-1,1'-biphenyl 
• 6050-13-1 biphenyl-2,2'-dicarboxylic acid anhydride 
• 5807-64-7 diphenic acid dimethyl ester 
• 38274-14-5 2,2'-bis-(bromomethyl)-1,1'-biphenyl 
• 3594-90-9 2,2'-bis(hydroxymethyl)biphenyl 

Relevant academic research and scientific papers

Biocatalytic Routes to Enantiomerically Enriched Dibenz[c,e]azepines

Biocatalytic retrosynthetic analysis of dibenz[c,e]azepines has highlighted the use of imine reductase (IRED) and ω-transaminase (ω-TA) biocatalysts to establish the key stereocentres of these molecules. Several enantiocomplementary IREDs were identified

Asymmetric activation of tropos catalysts in the stereoselective catalytic conjugate additions of R2Zn to α,β-enones: An efficient synthesis of (-)-muscone

The preparation of a new phosphoramidite starting from (R)-BINOL and a biphenylamine is presented. In such a compound the chirality is due only to atropisomerism and this molecule possesses a flexible biphenylamine residue. Therefore it can work as a tropos catalyst. The catalytic efficiency of this new phosphoramidite has been tested in some asymmetric conjugate additions of dialkylzinc reagents to α,β-enones and compared with that of an analogous already known non-tropos ligand. Interestingly, while comparable results were obtained in the addition of ZnEt2 to chalcone and cyclohexenone, in the case of the addition of ZnMe2 to (E)-cyclopentadec-2-en-1-one, the new ligand provides (-)-muscone, a valuable ingredient of the perfume industry, in 84% ee, while the non-tropos ligand gives a much lower (57%) ee value. Graphical Abstract

Novel derivatives and analogues of galanthamin

New compounds of general formula I 1

A facile synthesis of 6-alkyl-6,7-dihydro-5H-dibenz[c,e]azepines: Potent hypolipidemics

6-Alkyl-6,7-dihydro-5H-dibenz[c,e]azepines were synthesized in two steps in 63-88% overall yield by utilizing an efficient borane-tetrahydrofuran reduction of imides.

Hypolipidemic activity of phthalimide derivatives V: Reduced and hydrolytic products of simple cyclic imides

A series of cyclic imides and related compounds have previously been shown to possess hypolipidemic activity at the low dose level of 20 mg/kg/d. Hydrolytic and reduced products of the cyclic imides were synthesized and examined to discern if possible metabolic products were the active chemical species of these hypolipidemic agents. Phthalimide proved to be the most active cyclic imide tested. Unfortunately, the new products did not, in general, improve hypolipidemic activity in rodents. The exceptions were piperidine which demonstrated improved hypotriglyceridemic activity, and 3,4,5,6-dibenzohomopiperidin-2-one, which demonstrated improved hypocholesterolemic activity compared to phthalimide.

Fibrin stabilizing factor inhibitors. 12. 5 dibenzylaminopentylamine and related compounds, a new type of FSF inhibitors

A series of omega dibenzylaminoalkylamines and related compounds have been prepared and tested as inhibitors of fibrin cross linking. This structural type was chosen in an attempt to develop noncompetitive inhibitors of fibrinoligase. By the combination o